Search Results

It was great to bring everyone together and also welcome new member John Parkinson."

September 2022 "Parkinson’s disease (PD) as a progressive neurodegenerative disorder arises from multiple

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel way to treat pain without the negative side effects "Many people are familiar with cannabis, but John

Join the #GPCR movement by becoming a site member for FREE!

Join us now ➡️ https://www.ecosystem.drgpcr.com/dr-gpcr-summit-2022 #gpcr #drgpcr

🔬Join the #GPCR movement today! ➡️ https://www.ecosystem.drgpcr.com/plans-pricing #gpcr #drgpcr

Boston, MA and Santiago de Compostela, Spain — [June 3rd, 2025]  — Dr. GPCR, the global knowledge hub for G protein-coupled receptor (GPCR) research and education, is proud to welcome Celtarys Research to its partner ecosystem. This collaboration aims to amplify the visibility and adoption of Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics. Celtarys Research develops high-quality, fluorescently labeled ligands and innovative chemical biology tools to support real-time, non-radioactive GPCR assays. These tools enable high-resolution binding studies, kinetic analysis, and live-cell imaging, empowering both academic and industrial scientists to uncover GPCR biology with greater precision and speed. As a Dr. GPCR partner, Celtarys will be featured across multiple touchpoints in the ecosystem, including the Dr. GPCR Newsletter , University Courses , and Podcast , as well as the searchable Dr. GPCR Ecosystem Directory —a centralized hub for tools, training, and technology. “We’re thrilled to partner with Celtarys and introduce their high-performance fluorescent ligands to our global GPCR community,”  said Dr. Yamina Berchiche , Founder and CEO of Dr. GPCR. “These tools can dramatically improve how scientists measure ligand-receptor interactions, visualize binding in live cells, and design better experiments, core to advancing GPCR-targeted discovery.” “Dr. GPCR provides a unique platform to reach scientists at every stage of GPCR research,”  said Wilson Gomes , CEO of Celtarys Research. “This partnership will help accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic breakthroughs.” “We’re excited to support the GPCR community with tools that deliver clarity, sensitivity, and speed,”  added Dr. Maria Majellaro , CSO of Celtarys. “Working with Dr. GPCR allows us to engage with researchers worldwide who are shaping the future of receptor-targeted therapies.” To explore Celtarys Research’s catalog and learn more about their GPCR tools, visit  www.celtarys.com . For access to Dr. GPCR’s global network, educational content, and discovery tools, visit  ecosystem.drgpcr.com . ___________ About Dr. GPCR Dr. GPCR is a nonprofit organization connecting the global GPCR community through training, curated news, expert-led courses, and networking. With over 160 podcast episodes, live and on-demand educational programs, and a dynamic partner ecosystem, Dr. GPCR empowers scientists and companies advancing receptor biology and drug discovery. About Celtarys Research Celtarys Research is a biotech company based in Spain that specializes in the development of optimal chemical tools for drug discovery. Their proprietary chemistry platform enables rapid generation of conjugates, such as labeled ligands, with excellent affinity and pharmacological profiles, designed to advance GPCR-targeted assay development, screening, and live-cell imaging.

Come join us from October 10 to 16 to hear about exciting #GPCR research from amazing speakers.

February 2022 "Switzerland Today, InterAx Biotech is pleased to announce that Carola Weiss has joined

January 2022 "OXFORD, England--Professor Charlotte Deane, Ph.D., of the University of Oxford, has joined Professor Deane joins Exscientia’s technology leadership team, reporting to Chief Technology Officer,

This includes diseases such as depression, Parkinson’s, schizophrenia, and Alzheimer’s. GPR6 has been linked to neuroprotective functions and is now being investigated for its role in Parkinson GPR37 has been linked to the Parkinson’s disease as well, though more focused on the progression of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases, such as Parkinson

Join Dr. Dopamine D2 receptor modulators  – transforming treatment for Parkinson’s & schizophrenia. discovery or clinical development, the strategies here could open doors in your own therapeutic area. 🧭  Join Let’s move GPCR drug discovery forward — together. 🚨 Mark your calendar for the GPCR Happy Hour Join

John Teye Azietaku for his contributor article on Unveiling GPCR Priming: The Hidden Synergy in Cellular Join us in vibrant Mexico City from October 23 to 25, 2024, for this key event in adhesion GPCR Biology Science Post-Doctoral Fellow—Pharmacology/Cell Biology/Biochemistry Post Doctoral Fellow Postdoc Position Join

As a lab technician at Johns Hopkins, he was fascinated by science but also grounded in real-life responsibilities

nervous system and neurologic disorders, particularly movement disorders like dyskinesia associated with Parkinson's

His new obsession led him to Johns Hopkins, where he worked in the lab of Dr.

the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson's

neuropsychiatric diseases including Amyotrophic lateral sclerosis, Alzheimer's disease, Huntington's disease, Parkinson's

Join us for a discussion session on Kumospace, replacing the poster session. cardiometabolic disease GPCRs in Neuroscience Quinpirole ameliorates nigral dopaminergic neuron damage in Parkinson's Christophe Arbet-Engels to Join as Chief Medical Officer GPCR Events, Meetings, and Webinars ONCORNET2.0

Continue to increase your knowledge of Pharmacology by joining this practical approach class today. GPCR Partnered Events April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join the Endocrine Metabolic GPCRs bioinformatics analysis Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism Feeding Behavior Director of Laboratory Operations - Single-molecule Imaging Center Scientific Assistant Join

This Week’s Highlights: Congrats to: John Teye Azietaku , our great contributor, for his article Class

and D1R antagonism, kurarinone might be a potential compound that can alleviate clinical symptoms of Parkinson's

GPCR University February 8 - 29: Join Dr. GPCR University's live course with Dr. Terry Kenakin. April 22 - 23, 2024 | Endocrine Metabolic GPCRs Join us at the Endocrine Metabolic GPCRs event on April MolFlux: Empowering the ML Community in Molecular Predictive Modelling NanoImaging Services Appoints John

rat retrosplenial cortex Unveiling the therapeutic prospects of EGFR inhibition in rotenone-mediated parkinsonism GPCR Drug Discovery Biologist Post-Doctoral Scientist- Molecular Pharmacology (FDE) Research Assistant Join

Molecular determinants of ligand efficacy and potency in GPCR signaling Save the date: February 8 - 29: Join application of optogenetically functionalized Drosophila dopamine receptors Targeting CB2R in astrocytes for Parkinson's

Save the date: February 8 - 29: Join Dr. GPCR University's live Zoom sessions hosted by Dr. Meaningful Proof-of-Concept Data From Phase 2a Clinical Study Neurocrine opening two Phase 1 trials in oral Parkinson

beneficial pharmacological effects in the treatment of several neurological disorders including, epilepsy, Parkinson

It is involved in several pathophysiological processes such as Parkinson’s disease, depression, addiction Cannabinoid Receptor Type 1 in Parkinson’s Disease: A Positron Emission Tomography Study with [ 18 F   A.; Bohn, L. M.; Makriyannis, A.; Stevens, R. C.; Liu, Z.-J. J.; Wang, J.; Wu, M.; Katritch, V.; Zhao, S.; Kunos, G.; Bohn, L. M.; Makriyannis, A.; Stevens, R.

contributes to inflammatory joint pain Luke A Pattison , Rebecca H Rickman , Graham Ladds , Ewan St John

This week's highlight includes congrats to: John Teye Azietaku for his first contributor article on Illuminating - Global Research Technologies Novo Nordisk Scientist I - Global Research Technologies Novo Nordisk Join